DE60226429D1 - Diagnose der alzheimer-krankheit auf basis von mitogenaktivierter proteinkinase-phosphorylierung - Google Patents
Diagnose der alzheimer-krankheit auf basis von mitogenaktivierter proteinkinase-phosphorylierungInfo
- Publication number
- DE60226429D1 DE60226429D1 DE60226429T DE60226429T DE60226429D1 DE 60226429 D1 DE60226429 D1 DE 60226429D1 DE 60226429 T DE60226429 T DE 60226429T DE 60226429 T DE60226429 T DE 60226429T DE 60226429 D1 DE60226429 D1 DE 60226429D1
- Authority
- DE
- Germany
- Prior art keywords
- alzheimer
- mitogen
- diagnosis
- protein kinase
- activated protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- G01N2333/91205—Phosphotransferases in general
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US27141601P | 2001-02-27 | 2001-02-27 | |
US32950501P | 2001-10-17 | 2001-10-17 | |
PCT/US2002/005672 WO2002067764A2 (en) | 2001-02-27 | 2002-02-27 | Alzheimer's disease diagnosis based on mitogen-activated protein kinase phosphorylation |
Publications (1)
Publication Number | Publication Date |
---|---|
DE60226429D1 true DE60226429D1 (de) | 2008-06-19 |
Family
ID=26954877
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE08002964T Pending DE08002964T1 (de) | 2001-02-27 | 2002-02-27 | Alzheimer-Diagnose auf Basis von mitogenaktivierter Proteinkinasephosphorylierung |
DE60226429T Expired - Lifetime DE60226429D1 (de) | 2001-02-27 | 2002-02-27 | Diagnose der alzheimer-krankheit auf basis von mitogenaktivierter proteinkinase-phosphorylierung |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE08002964T Pending DE08002964T1 (de) | 2001-02-27 | 2002-02-27 | Alzheimer-Diagnose auf Basis von mitogenaktivierter Proteinkinasephosphorylierung |
Country Status (10)
Country | Link |
---|---|
US (3) | US7682807B2 (de) |
EP (1) | EP1385531B1 (de) |
JP (3) | JP4246495B2 (de) |
KR (2) | KR100941597B1 (de) |
CN (1) | CN1549721B (de) |
AT (1) | ATE394115T1 (de) |
AU (1) | AU2002254029A1 (de) |
DE (2) | DE08002964T1 (de) |
ES (2) | ES2305234T3 (de) |
WO (1) | WO2002067764A2 (de) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE08002964T1 (de) * | 2001-02-27 | 2009-09-03 | Blanchette Rockefeller Neurosciences Institute | Alzheimer-Diagnose auf Basis von mitogenaktivierter Proteinkinasephosphorylierung |
AU2003298680A1 (en) | 2002-11-27 | 2004-06-23 | Sugen, Inc. | Phosphospecific pak antibodies and diagnostic kits |
US20060040338A1 (en) * | 2004-08-18 | 2006-02-23 | Odyssey Thera, Inc. | Pharmacological profiling of drugs with cell-based assays |
US20060094059A1 (en) * | 2004-09-22 | 2006-05-04 | Odyssey Thera, Inc. | Methods for identifying new drug leads and new therapeutic uses for known drugs |
CN101061237A (zh) * | 2004-11-15 | 2007-10-24 | 布朗歇特洛克菲勒神经科学研究所 | 磷酸酶2a(pp2a)异常用于诊断与治疗阿耳茨海默病 |
AR053272A1 (es) * | 2005-05-11 | 2007-04-25 | Hoffmann La Roche | Determinacion de responsivos a la quimioterapia |
WO2007044094A1 (en) * | 2005-10-11 | 2007-04-19 | Blanchette Rockefeller Neurosciences Institute | Alzheimer's disease-specific alterations of the erk1/erk2 phosphorylation ratio as alzheimer's disease-specific molecular biomarkers (adsmb) |
WO2007043998A1 (en) * | 2005-10-11 | 2007-04-19 | Blanchette Rockefeller Neurosciences Institute | Alzheimer’s disease-specific alterations of the erk1/erk2 phosphorylation ratio |
EP1934618B1 (de) * | 2005-10-11 | 2009-05-13 | Blanchette Rockefeller Neurosciences Institute | Morbus alzheimer-spezifische veränderungen des erk1/erk2-phosphorylierungsverhältnisses - morbus alzheimer-spezifische molekulare biomarker (adsmb) |
US20090029873A1 (en) * | 2005-10-11 | 2009-01-29 | Blanchette Rockefeller Neurosciences Institute | Alzheimer's Disease-Specific Alterations of the Erk1/Erk2 Phosphorylation Ratio-Alzheimer's Disease-Specific Molecular Biomarkers (Adsmb) |
US20080221042A1 (en) * | 2005-10-11 | 2008-09-11 | Tapan Kumar Khan | Alzheimer's disease-specific alterations of the ERK1/ERK2 Phosphorylation ratio-Alzheimer's disease-specific molecular biomarkers (ADSMB) |
US7595167B2 (en) | 2005-10-11 | 2009-09-29 | Blanchette Rockefeller Neurosciences Institute | Alzheimer's disease-specific alterations of the Erk1/Erk2 phosphorylation ratio |
GB0708075D0 (en) * | 2007-04-26 | 2007-06-06 | Univ Nottingham | Nethods |
EP3586839A1 (de) | 2008-07-28 | 2020-01-01 | Blanchette Rockefeller Neurosciences, Institute | Pkc-aktivierende verbindungen zur behandlung von neurodegenerativen erkrankungen |
EP2669386A1 (de) * | 2008-07-28 | 2013-12-04 | Blanchette Rockefeller Neurosciences Institute | Stimulierte ausgelöste genomische Profilmarker von Morbus Alzheimer |
US20110172501A1 (en) * | 2008-08-27 | 2011-07-14 | Irina Antonijevic | System and methods for measuring biomarker profiles |
CA2776501C (en) * | 2009-10-02 | 2022-04-19 | Blanchette Rockefeller Neurosciences Institute | Fibroblast growth patterns for diagnosis of alzheimer's disease |
CN102741696A (zh) | 2009-10-02 | 2012-10-17 | 布朗歇特洛克菲勒神经科学研究所 | 阿尔茨海默病外周细胞中pkc同工酶加工的异常改变 |
EP2780316B1 (de) | 2011-11-13 | 2020-04-15 | Blanchette Rockefeller Neurosciences Institute | Ester von dcpla und behandlungsverfahren damit |
ES2495266B8 (es) | 2013-02-13 | 2015-11-12 | Consejo Superior De Investigaciones Científicas (Csic) | Uso de igf-1 como reactivo de diagnóstico y/o pronóstico precoz de la enfermedad de alzheimer |
ES2973048T3 (es) * | 2013-12-27 | 2024-06-18 | Univ Nat Corp Tokyo Medical & Dental | Método para el diagnóstico de la enfermedad de Alzheimer y la degeneración lobar frontotemporal, agente de diagnóstico, agente terapéutico y método de cribado ("screening") para dichos agentes |
ES2598885B1 (es) * | 2015-06-30 | 2017-10-09 | Consejo Superior De Investigaciones Científicas | Método para determinar el riesgo de desarrollar la enfermedad de Alzheimer |
CN106442963B (zh) * | 2016-09-14 | 2018-09-14 | 江苏康缘药业股份有限公司 | 一种检测引起类过敏反应的物质的方法及其试剂盒 |
WO2018183703A1 (en) | 2017-03-31 | 2018-10-04 | NeuroDiagnostics LLC | Lymphocyte-based morphometric test for alzheimer's disease |
AU2018300159A1 (en) | 2017-07-12 | 2020-02-06 | Texas Tech University System | MicroRNA-455-3p as a peripheral biomarker for Alzheimer's disease |
CN111918875A (zh) * | 2018-03-11 | 2020-11-10 | 库罗什·沙帕桑 | 构象-特异性的抗神经毒性tau蛋白的抗体 |
KR102295114B1 (ko) * | 2019-12-30 | 2021-08-27 | 경상국립대학교산학협력단 | 알츠하이머 병기 예측용 조성물 및 상기 조성물을 이용한 예측 키트 |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6080784A (en) | 1986-06-11 | 2000-06-27 | Procyon Pharmaceuticals, Inc. | Protein kinase C modulators N |
US5242932A (en) * | 1991-12-17 | 1993-09-07 | The Rockefeller University | Treatment of amyloidosis associated with alzheimer disease |
US5385915A (en) * | 1990-05-16 | 1995-01-31 | The Rockefeller University | Treatment of amyloidosis associated with Alzheimer disease using modulators of protein phosphorylation |
DK0618968T3 (da) * | 1991-12-06 | 2000-04-10 | Max Planck Gesellschaft | Midler til diagnostisering og behandling af Alzheimer's sygdom |
US20030108956A1 (en) | 1993-05-03 | 2003-06-12 | Alkon Daniel L. | Cell tests for Alzheimer's disease |
US5976816A (en) * | 1993-05-03 | 1999-11-02 | The United States Of America As Represented By The Department Of Health And Human Services | Cell tests for alzheimer's disease |
US6107050A (en) * | 1993-05-03 | 2000-08-22 | The United States Of America As Represented By The Department Of Health And Human Services | Diagnostic test for alzheimers disease |
US7625697B2 (en) | 1994-06-17 | 2009-12-01 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for constructing subarrays and subarrays made thereby |
EP0791067B1 (de) * | 1994-10-28 | 2008-12-17 | Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E.V. | Proteinkinase npk-110 |
US6001580A (en) | 1995-03-28 | 1999-12-14 | Takeda Chemical Industries, Inc. | Method for assaying ERK2 map kinase |
CN1189816A (zh) * | 1995-05-01 | 1998-08-05 | 匹兹堡大学 | 用于阿尔茨海默氏病死亡前诊断以及体内成像和防止淀粉样蛋白沉积的偶氮化合物 |
AU2316797A (en) | 1996-02-29 | 1997-09-16 | Mount Sinai Hospital Corporation | Shc proteins |
JPH1090263A (ja) | 1996-07-25 | 1998-04-10 | Mclean Hospital Corp:The | アルツハイマー病の診断のためのerk−1およびerk−2の利用 |
GB9803399D0 (en) * | 1998-02-19 | 1998-04-15 | Imp Cancer Res Tech | Protein kinase c |
JP2002526775A (ja) * | 1998-10-01 | 2002-08-20 | テイテイエブスキ,アレクセイ・ウラデイミロビチ | GDNFについての新規Ret非依存性シグナリング経路 |
EP1208228A2 (de) | 1999-05-19 | 2002-05-29 | Mitokor | Differentielle genexpression in spezifischen regionen vom gehirn in neurodegenerativen erkrankungen |
WO2001027624A2 (en) | 1999-10-08 | 2001-04-19 | Superarray, Inc. | Compositions and methods for detecting protein modification and enzymatic activity |
US20030165481A1 (en) | 2000-02-24 | 2003-09-04 | Hersh Louis B. | Amyloid peptide inactivating enzyme to treat Alzheimer's disease |
AU2001247369A1 (en) | 2000-03-10 | 2001-09-24 | Washington University | Method for labeling individual cells |
CA2417744A1 (en) | 2000-07-31 | 2002-02-07 | The Regents Of The University Of California | Model for alzheimer's disease and other neurodegenerative diseases |
AUPR215700A0 (en) | 2000-12-19 | 2001-01-25 | Fujisawa Pharmaceutical Co., Ltd. | Carboxylic acid compound having cyclopropane ring |
EP1358329A2 (de) | 2001-02-06 | 2003-11-05 | Incyte Genomics, Inc. | Lipid-assoziierte moleküle |
DE08002964T1 (de) | 2001-02-27 | 2009-09-03 | Blanchette Rockefeller Neurosciences Institute | Alzheimer-Diagnose auf Basis von mitogenaktivierter Proteinkinasephosphorylierung |
US20040014678A1 (en) * | 2001-08-08 | 2004-01-22 | Antonella Favit | Prevention of beta-amyloid neurotoxicity by blockade of the ubiquitin-proteasome proteolytoc pathway |
WO2004083241A2 (en) | 2003-03-19 | 2004-09-30 | Takeda Pharmaceutical Company Limited | Btc-interacting proteins and use thereof |
US7595159B2 (en) | 2004-11-03 | 2009-09-29 | The Brigham And Women's Hospital, Inc. | Prediction of Parkinson's disease using gene expression levels of peripheral blood samples |
CN101061237A (zh) | 2004-11-15 | 2007-10-24 | 布朗歇特洛克菲勒神经科学研究所 | 磷酸酶2a(pp2a)异常用于诊断与治疗阿耳茨海默病 |
WO2007044094A1 (en) | 2005-10-11 | 2007-04-19 | Blanchette Rockefeller Neurosciences Institute | Alzheimer's disease-specific alterations of the erk1/erk2 phosphorylation ratio as alzheimer's disease-specific molecular biomarkers (adsmb) |
WO2007043998A1 (en) | 2005-10-11 | 2007-04-19 | Blanchette Rockefeller Neurosciences Institute | Alzheimer’s disease-specific alterations of the erk1/erk2 phosphorylation ratio |
EP1934618B1 (de) | 2005-10-11 | 2009-05-13 | Blanchette Rockefeller Neurosciences Institute | Morbus alzheimer-spezifische veränderungen des erk1/erk2-phosphorylierungsverhältnisses - morbus alzheimer-spezifische molekulare biomarker (adsmb) |
US20090029873A1 (en) * | 2005-10-11 | 2009-01-29 | Blanchette Rockefeller Neurosciences Institute | Alzheimer's Disease-Specific Alterations of the Erk1/Erk2 Phosphorylation Ratio-Alzheimer's Disease-Specific Molecular Biomarkers (Adsmb) |
US7595167B2 (en) * | 2005-10-11 | 2009-09-29 | Blanchette Rockefeller Neurosciences Institute | Alzheimer's disease-specific alterations of the Erk1/Erk2 phosphorylation ratio |
US20070299360A1 (en) | 2006-06-21 | 2007-12-27 | Lexicor Medical Technology, Llc | Systems and Methods for Analyzing and Assessing Dementia and Dementia-Type Disorders |
EP2121000B1 (de) | 2007-02-09 | 2015-09-23 | Blanchette Rockefeller Neurosciences, Institute | Therapeutische wirkungen von bryostatinen, bryologen und anderen damit zusammenhängenden substanzen auf durch kopftraumata herbeigeführte gedächtnisstörungen und hirnverletzungen |
US20100209914A1 (en) | 2007-05-25 | 2010-08-19 | Ore Pharmaceuticals , Inc. | Methods, systems, and kits for evaluating multiple sclerosis |
-
2002
- 2002-02-27 DE DE08002964T patent/DE08002964T1/de active Pending
- 2002-02-27 DE DE60226429T patent/DE60226429D1/de not_active Expired - Lifetime
- 2002-02-27 AU AU2002254029A patent/AU2002254029A1/en not_active Abandoned
- 2002-02-27 CN CN028078322A patent/CN1549721B/zh not_active Expired - Lifetime
- 2002-02-27 US US10/469,164 patent/US7682807B2/en not_active Expired - Lifetime
- 2002-02-27 ES ES02723236T patent/ES2305234T3/es not_active Expired - Lifetime
- 2002-02-27 EP EP02723236A patent/EP1385531B1/de not_active Expired - Lifetime
- 2002-02-27 JP JP2002567141A patent/JP4246495B2/ja not_active Expired - Lifetime
- 2002-02-27 KR KR1020037011307A patent/KR100941597B1/ko active IP Right Grant
- 2002-02-27 AT AT02723236T patent/ATE394115T1/de not_active IP Right Cessation
- 2002-02-27 KR KR1020097004352A patent/KR100960256B1/ko active IP Right Grant
- 2002-02-27 ES ES08002964T patent/ES2325350T1/es active Pending
- 2002-02-27 WO PCT/US2002/005672 patent/WO2002067764A2/en active Application Filing
-
2008
- 2008-11-07 JP JP2008286869A patent/JP5253971B2/ja not_active Expired - Lifetime
-
2010
- 2010-03-22 US US12/729,042 patent/US9188595B2/en not_active Expired - Lifetime
-
2012
- 2012-12-07 JP JP2012268633A patent/JP2013078330A/ja active Pending
-
2015
- 2015-11-16 US US14/942,758 patent/US20160305961A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20160305961A1 (en) | 2016-10-20 |
EP1385531A2 (de) | 2004-02-04 |
US20050059092A1 (en) | 2005-03-17 |
EP1385531B1 (de) | 2008-05-07 |
KR100960256B1 (ko) | 2010-06-01 |
KR100941597B1 (ko) | 2010-02-11 |
JP5253971B2 (ja) | 2013-07-31 |
CN1549721B (zh) | 2012-03-07 |
CN1549721A (zh) | 2004-11-24 |
US9188595B2 (en) | 2015-11-17 |
AU2002254029A1 (en) | 2002-09-12 |
JP2013078330A (ja) | 2013-05-02 |
EP1385531A4 (de) | 2004-05-12 |
JP2009148247A (ja) | 2009-07-09 |
US20100278803A1 (en) | 2010-11-04 |
KR20090038922A (ko) | 2009-04-21 |
JP4246495B2 (ja) | 2009-04-02 |
JP2004533218A (ja) | 2004-11-04 |
ES2325350T1 (es) | 2009-09-02 |
DE08002964T1 (de) | 2009-09-03 |
ES2305234T3 (es) | 2008-11-01 |
WO2002067764A3 (en) | 2002-11-14 |
KR20040086145A (ko) | 2004-10-08 |
ATE394115T1 (de) | 2008-05-15 |
WO2002067764A2 (en) | 2002-09-06 |
US7682807B2 (en) | 2010-03-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60226429D1 (de) | Diagnose der alzheimer-krankheit auf basis von mitogenaktivierter proteinkinase-phosphorylierung | |
Minami et al. | Seasonal variations in office, home and 24 h ambulatory blood pressure in patients with essential hypertension | |
Belew et al. | Evaluation of the white‐coat effect in cats | |
SE9904087D0 (sv) | Recommended replacement time of an implantable medical device | |
ATE491389T1 (de) | Nichtinvasives verfahren und vorrichtung zur überwachung kardiologischer parameter | |
SE9103332L (sv) | Metod foer diagnos av blodkoagulationssjukdomar | |
ATE442851T1 (de) | 1-deoxy-galactonojirimycin-derivate zur vewendung bei der behandlung von lysosomalen speicherkrankheiten mittels steigerung der lysosomalen alpha galactosidase a | |
DE60210939D1 (de) | Gerät zur bestimmung des hämodynamischen zustands | |
BRPI0416542A (pt) | determinação automática de um parámetro cardiovascular baseada na pressão arterial | |
ATE523797T1 (de) | Vorrichtung zur herzelastographie | |
ATE451477T1 (de) | Diagnose und überwachung von hepatozellulärem karzinom | |
Kario et al. | The influence of work-and home-related stress on the levels and diurnal variation of ambulatory blood pressure and neurohumoral factors in employed women | |
Barriga et al. | Adequate illumination for otoscopy: variations due to power source, bulb, and head and speculum design | |
Julius et al. | Comparison of various clinical measurements of blood pressure with the self-determination technique in normotensive college males | |
EP1925315A3 (de) | Alzheimer-Diagnose auf Basis von mitogenaktivierter Proteinkinasephosphorylierung | |
Fariello et al. | Ambulatory-determined 24-hour blood pressure in mild hypertensives and in normotensives | |
ATE337020T1 (de) | Fettsaure analoge zur diagnose von kranzarterie erkrankungen | |
BR0209681A (pt) | Método e kit para o diagnóstico in vivo ou para o monitoramento de uma doença que envolve uma reação inflamatória dentro de um paciente | |
Addison et al. | The use of ambulatory blood pressure monitoring in managing hypertension according to different treatment guidelines | |
ATE554790T1 (de) | Verfahren und zusammensetzungen zur diagnose von asthma | |
SE0102220D0 (sv) | Method for estimation of the amount of specific cell types | |
RU2194437C2 (ru) | Способ ранней диагностики гипертонической болезни | |
RU98101085A (ru) | Способ диагностики заболеваний печени у собак | |
RU2001113027A (ru) | Способ диагностики тканевой инсулинорезистентности у различной категории кардиологических больных | |
RU2005132657A (ru) | Способ интегрального определения показателей центральной гемодинамики |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |